Looking To Learn From Past Failures, Galapagos Pivots To Immunology And CAR-T
200 Jobs Shed And Pipeline Cut Back
Executive Summary
The company has admitted making mistakes in its R&D, but must now convince investors that its new multi-modality approach will pay off.